After admitting mistake, AstraZeneca faces tough questions about vaccine



[ad_1]

Bigger problems quickly arose.

An AstraZeneca executive told Reuters on Monday that the company had not scheduled participants to receive the half dose. The British researchers who were running the trial there had wanted to give the full dose initially to the volunteers, but a miscalculation meant that they had mistakenly received only a half dose. The executive, Menelas Pangalos, described the error as a “fluke”, allowing the researchers to come up with a more promising dosage regimen.

For many outside experts, this undermines the credibility of the results because tightly calibrated clinical trials were not designed to test the effectiveness of an initial dose at half strength.

The company’s initial announcement did not mention the accidental nature of the find.

In the statement attributed to Oxford, Ms Meixell, spokeswoman for AstraZeneca, said the error stemmed from an issue, which has since been resolved, with the way some of the vaccine doses were made.

Then, on Tuesday, Moncef Slaoui, the head of Operation Warp Speed, the US initiative to speed up coronavirus vaccines, noted another limitation in AstraZeneca data. On a call with reporters, he suggested that participants who received the initial half-strength dose were 55 or younger. Ms Meixell declined to say whether this was the case, noting that the data would soon be published in a peer-reviewed journal.

If the initial half-dose were not tested in older participants, who are particularly vulnerable to Covid-19, it would hurt AstraZeneca’s case for regulators that the vaccine should be cleared for emergency use.

Food and Drug Administration spokesperson Stephanie Caccomo declined to say whether the dosing error would hurt the vaccine’s chances of being cleared. The FDA has said it expects the vaccines to be at least 50% effective in preventing or reducing the severity of the disease, a bar the vaccine appears to have eliminated even in the group that received both doses. complete.

AstraZeneca shares have fallen about 5% this week, while broader stock indexes have hit record highs. Investors appear disappointed with the murky results, especially compared to the much clearer data released by two of AstraZeneca’s main rivals in the coronavirus vaccine race.

[ad_2]

Source link